Amgen just added roughly 5% in market value in a single session, with the stock jumping to about US$408, and the move tracks a quarter that gave investors something concrete to latch onto. Q2 revenue crossed US$10b and basic earnings per share landed above US$4. The bigger story sits on a longer time frame. Trailing 12 month earnings are now above US$16 per share and management has lifted full year guidance, which keeps the focus on whether this earnings run can support a valuation that still screens below a discounted cash flow fair value estimate.

Is Amgen a genuine mispricing at a reported 38.9% discount to the DCF fair value, or is the higher P/E versus the biotech industry doing the heavy lifting here? Compare that gap against cash flows, growth assumptions and peer multiples on the valuation analysis for Amgen

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$10,054m vs. US$9,179m (up roughly 10%)
• Net Income, Q2 2026 vs. Q2 2025: US$2,375m vs. US$1,432m (up about 66%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$4.40 vs. US$2.66 (up about 65%)
• Products Approved, Q2 2026 vs. Q2 2025: 0 vs. 1 (lower product approval count this quarter)

Prefer clean charts instead of scrolling through more tables and raw figures on Amgen? See the full visual breakdown of Amgen's valuation picture in the company report for Amgen..

Amgen’s Growth Story Clears Key Execution Hurdles

The bullish view on Amgen is that broad volume growth and a maturing late stage pipeline can offset loss of exclusivity and turn 2026 into a springboard year. Q2 results go a long way toward proving that. Revenue moved above US$10b and management lifted full year revenue and non GAAP EPS guidance, which is a concrete milestone for any growth narrative.

The more specific claim is that newer drugs and biosimilars can carry the load. Management now attributes roughly 70% of product sales to six growth drivers and says this group grew about 26% year on year, helped by Repatha, EVENITY, TEZSPIRE, rare disease assets, oncology and biosimilars. That progress is offsetting erosion in Prolia/XGEVA and the loss of AMG 513 in obesity. The portfolio mix is already tilting toward the franchises that the bullish thesis depends on, which is an important box ticked for that narrative.

Reveal where the surface looks calm but the models quietly diverge, and see where the street might be bracing for the next earnings inflection. Access the full multi year analyst estimates for Amgen.

Amgen’s Risk Stack: Strong Quarter, Key Holes Exposed

The bearish view is that Amgen’s growth engine sits on fragile foundations, with regulatory, product concentration and integration risks that could cap long term returns. Q2 results partly challenge this, but several milestones are clearly missed. The loss of obesity asset AMG 513 leaves MariTide carrying far more of the future weight loss story. Prolia/XGEVA already show sharp erosion, which validates fears around patent cliffs and margin pressure as legacy products face competition.

Regulatory and governance worries are not clearing. Tavneos is in a multi region safety and data integrity crisis and the timeline to resolution is unclear. The IRS audit for 2016 to 2018, patent litigation damages that could be increased, quality related recalls and a fresh cybersecurity breach all keep the risk overhang in place. Strong growth across the six listed drivers helps, but it does not yet disprove the bears’ concern that the risk stack is building faster than the pipeline can de risk it.

After regulatory setbacks, product erosion and high debt, are these visible issues masking deeper structural pressure points? Review the full risk analysis for Amgen which shows 1 important warning sign.

Stay Ahead With Simply Wall St

If Amgen’s valuation gap and recent guidance raise questions for you, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch for a better entry point. After you own the stock, keep your decisions clear and focused with the Portfolio Command Center that highlights only the key developments that may matter for your holdings. For a broader view, use the Community to see how other investors are thinking about Amgen and similar stocks. By spotting potential catalysts and risks early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Amgen Right Now

Fresh ideas move first when momentum builds. Some stocks are already setting up for potential breakouts while others drop off the radar. Before the edge fades, get in early.

• Spot potential income anchors that aim to keep paying investors while prices move, then scan a curated set of higher yielding candidates with the 8 dividend fortresses.
• Hunt for companies where balance sheets and fundamentals still look solid while prices have not fully caught up, using the curated list of solid balance sheet and fundamentals stocks (50 results).
• Target potential early movers in AI that already generate profits instead of just burning cash by checking the focused list in the 67 profitable AI stocks that aren't just burning cash.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.